HealthyPhase 1NCT07235150
A Study to Learn How Different Amounts of the Study Medicine Called PF-07985631 Are Tolerated and Act in the Body in Healthy Adults
A Phase 1 study testing PF-07985631 in people with Healthy, run by Pfizer at 1 site in Australia.
Trial summary
The purpose of this study is to learn about the safety and effects of the study medicine (called PF-07985631) for the possible treatment of a kidney disease called IgA nephropathy. Read more about this study
- Who is it for?
- Ages 18 to 55 yearsHealthy volunteers can take part
- Conditions the study is for
- Healthy
- What is being tested?
- PF-07985631
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 9 participants
- Where
- 1 siteAustralia
- Study dates
- 11 Dec 2025to 16 Jul 2026
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 55 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Between 18 and 45 years of age who are overtly healthy.
- Japanese/Chinese cohorts only: Adult participants 18 to 55 years of age
- Japanese/Chinese cohorts only: Participants must have 4 biological Japanese/Chinese grandparents who were born in Japan/China.
Who cannot join
- Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).
- Participants with a history of allergic or anaphylactic reaction with any investigative biologic agents.
- History of infections requiring treatment within 28 days prior to Day 1 or any active infection at Day 1.
- Active or latent infection with tuberculosis.
- History of recurrent urinary tract infections AND/OR sinopulmonary infections AND/OR gastrointestinal infections requiring antibiotic treatment.
- Known fever within the 7 days prior to dosing.
Show all 21Show fewer
- Active gastrointestinal (GI) tract ulcerations or GI bleeding.
- Vaccination within 6 weeks prior to Day 1 dosing or planned vaccination during the study.
- Positive urine drug test.
- Screening supine blood pressure (BP) ≥140 mm Hg (systolic) or ≥90 mm Hg (diastolic).
- Estimated glomerular filtration rate (eGFR) <75 mL/min/1.73 m².
- Chest X-ray showing any active disease in the chest, or pulmonary nodules >0.5 cm in diameter that have not been previously evaluated, cavitary lesions or evidence of bronchiectasis.
- Standard 12 lead ECG that demonstrates clinically relevant abnormalities that may affect participant safety or interpretation of study results.
- Positive stool hematest at screening or admission.
- Participants with ANY of the following abnormalities in clinical laboratory tests at screening:
- Alanine aminotransferase (ALT), aspartate aminotransferase (AST), bilirubin (direct and total) ≥1.05 × upper limit of normal
- Immunoglobulin G, Immunoglobulin M, Immunoglobulin A below the lower limit of normal (LLN)
- Total white blood cell (WBC) below the LLN
- Lymphocyte count below the LLN
- Platelet count below the LLN
- Hemoglobin below the LLN
Trial locations and contacts
1 site in 1 country.
Australia1 site
Q-Pharm Pty Ltd. (Nucleus Network)
Herston, Queensland, 4006
About this study
Official title: A PHASE 1, RANDOMIZED, MULTI-CENTER, DOUBLE-BLIND, SPONSOR OPEN, PLACEBO-CONTROLLED, SINGLE DOSE-ESCALATION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF PF-07985631 IN HEALTHY ADULT PARTICIPANTS
The purpose of this study is to learn about the safety and effects of the study medicine (called PF-07985631) for the possible treatment of a kidney disease called IgA nephropathy.
This study is seeking participants who
Read more
- are male or female between 18 and 45 years of age (55 for Japanese/Chinese/multiple dose participants)
- are deemed to be healthy Participants in this study will receive PF-07985631 or placebo. A placebo does not have any medicine in it but looks just like the medicine being studied.
PF-07985631 or placebo will be given as a small needle injection (in the abdomen, thigh or back of the arm) at the study clinic. Most participants will receive PF-07985631 or placebo one time. Some participants may receive PF-07985631 or placebo twice.
The study will compare the experiences of people receiving PF-07985631 to those of the people who do not. This will help decide if PF-07985631 is safe and effective.
Participants who take PF-07985631 or placebo will take part in this study for about four- four and a half months. During this time, they will stay at the study clinic for 12 to 19 days and will have 7 more study visits at the study clinic.
During study clinic stays and study visits, blood samples will be done and safety reviews completed.
- Conditions
- Healthy
- Being tested
- PF-07985631, Placebo
- Keywords
- healthy participants, healthy volunteers, safety
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PF-07985631Drug
Experimental Pfizer compound which will be SC
PlaceboDrug
Placebo which will be SC
| Study group | Role | What they receive |
|---|---|---|
| Cohort 1 Dose A (3 active: 2 placebo) | Experimental | Drug: PF-07985631 Experimental Pfizer compound which will be SC
Drug: Placebo Placebo which will be subcutaneous (SC) Receives: Drug: PF-07985631; Drug: Placebo |
| Cohort 8 Optional Cohort with dose to be determined, Japanese (4 active: 1 placebo) | Experimental | Drug: PF-07985631 Experimental Pfizer compound which will be SC
Drug: Placebo Placebo which will be SC Receives: Drug: PF-07985631; Drug: Placebo |
| Cohort 7 Dose G (6 active: 2 placebo) | Experimental | Drug: PF-07985631 Experimental Pfizer compound which will be SC
Drug: Placebo Placebo which will be SC Receives: Drug: PF-07985631; Drug: Placebo |
| Cohort 6 Dose F (6 active: 2 placebo) | Experimental | Drug: PF-07985631 Experimental Pfizer compound which will be SC
Drug: Placebo Placebo which will be SC Receives: Drug: PF-07985631; Drug: Placebo |
| Cohort 2 Dose B (3 active: 2 placebo) | Experimental | Drug: PF-07985631 Experimental Pfizer compound which will be SC
Drug: Placebo Placebo which will be SC Receives: Drug: PF-07985631; Drug: Placebo |
| Cohort 4 Dose D (6 active: 2 placebo) | Experimental | Drug: PF-07985631 Experimental Pfizer compound which will be SC
Drug: Placebo Placebo which will be SC Receives: Drug: PF-07985631; Drug: Placebo |
| Cohort 5 Dose E (6 active: 2 placebo) | Experimental | Drug: PF-07985631 Experimental Pfizer compound which will be SC
Drug: Placebo Placebo which will be SC Receives: Drug: PF-07985631; Drug: Placebo |
| Cohort 9 Optional Cohort with dose to be determined, Chinese (4 active: 1 placebo) | Experimental | Drug: PF-07985631 Experimental Pfizer compound which will be SC
Drug: Placebo Placebo which will be SC Receives: Drug: PF-07985631; Drug: Placebo |
| Cohort 3 Dose C (6 active: 2 placebo) | Experimental | Drug: PF-07985631 Experimental Pfizer compound which will be SC
Drug: Placebo Placebo which will be SC Receives: Drug: PF-07985631; Drug: Placebo |
| Cohort 10 Optional Cohort with dose to be determined (6 active: 2 placebo) | Experimental | Drug: PF-07985631 Experimental Pfizer compound which will be SC
Drug: Placebo Placebo which will be SC Receives: Drug: PF-07985631; Drug: Placebo |
| Cohort 11 Optional Cohort with dose to be determined (6 active: 2 placebo) | Experimental | Drug: PF-07985631 Experimental Pfizer compound which will be SC
Drug: Placebo Placebo which will be SC Receives: Drug: PF-07985631; Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAE)
Measured: Baseline (Day 1) up to 83 days after last dose of study drug (approximately up to 3 months)
Number of Participants With Clinically Significant Abnormal Laboratory Parameters
Measured: Baseline (Day 1) up to 83 days after last dose of study drug (approximately up to 3 months)
Number of Participants With Vital Signs Values Meeting Categorical Summarization Criteria
Measured: Baseline (Day 1) up to 83 days after last dose of study drug (approximately up to 3 months)
Number of Participants With Notable Electrocardiogram (ECG) Values
Measured: Baseline (Day 1) up to 83 days after last dose of study drug (approximately up to 3 months)
Secondary outcomes (5)
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) as data permit
Measured: Predose (Day 1) up to 83 days after last dose of study drug (approximately up to 3 months)
Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) as data permit
Measured: Predose (Day 1) up to 83 days after last dose of study drug (approximately up to 3 months)
Maximum Observed Plasma Concentration (Cmax) as data permit
Measured: Predose (Day 1) up to 83 days after last dose of study drug (approximately up to 3 months)
Time to Reach Maximum Observed Plasma Concentration (Tmax) as data permit
Measured: Predose (Day 1) up to 83 days after last dose of study drug (approximately up to 3 months)
Plasma Decay Half-Life (t1/2) as data permit
Measured: Predose (Day 1) up to 83 days after last dose of study drug (approximately up to 3 months)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Nov 2025
- Study start11 Dec 2025
- Primary completion16 Jul 2026
- Study completion16 Jul 2026
Why it stopped: The estimated benefit-risk profile of PF-07985631 is not anticipated to be favorable in the expected population to be treated
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HealthyStudies of the same condition, open and under way.
- More trials run by PfizerThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 9 participants (actual)
Sponsor and investigators
- Lead sponsor
- Pfizer
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Pfizer CT.gov Call Center, Study director, Pfizer
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07235150
- Sponsor's protocol ID
- C5661003
- Status last verified
- Aug 2026
- First submitted
- 14 Nov 2025
- Last updated
- 18 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical\_trials/trial\_data\_and\_results/data\_requests.
Study at a glance
From the registry record, last updated by the sponsor on 18 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A PHASE 1, RANDOMIZED, MULTI-CENTER, DOUBLE-BLIND, SPONSOR OPEN, PLACEBO-CONTROLLED, SINGLE DOSE-ESCALATION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF PF-07985631 IN HEALTHY ADULT PARTICIPANTS
- ClinicalTrials.gov ID
- NCT07235150
- Acronym / sponsor ID
- C5661003
- Conditions
- Healthy
- Keywords
- healthy participants, healthy volunteers, safety
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: The estimated benefit-risk profile of PF-07985631 is not anticipated to be favorable in the expected population to be treated
- Enrolment
- 9 participants (actual)
- Lead sponsor
- PfizerIndustry (pharma, biotech, devices)
- Study start
- 11 Dec 2025 (actual)
- Primary completion
- 16 Jul 2026 (actual)
- Study completion
- 16 Jul 2026 (actual)
- First posted
- 19 Nov 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to learn about the safety and effects of the study medicine (called PF-07985631) for the possible treatment of a kidney disease called IgA nephropathy.
This study is seeking participants who
- are male or female between 18 and 45 years of age (55 for Japanese/Chinese/multiple dose participants)
- are deemed to be healthy Participants in this study will receive PF-07985631 or placebo. A placebo does not have any medicine in it but looks just like the medicine being studied.
PF-07985631 or placebo will be given as a small needle injection (in the abdomen, thigh or back of the arm) at the study clinic. Most participants will receive PF-07985631 or placebo one time. Some participants may receive PF-07985631 or placebo twice.
The study will compare the experiences of people receiving PF-07985631 to those of the people who do not. This will help decide if PF-07985631 is safe and effective.
Participants who take PF-07985631 or placebo will take part in this study for about four- four and a half months. During this time, they will stay at the study clinic for 12 to 19 days and will have 7 more study visits at the study clinic.
During study clinic stays and study visits, blood samples will be done and safety reviews completed.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 11
| Arm | Type | Receives |
|---|---|---|
| Cohort 1 Dose A (3 active: 2 placebo) | Experimental | Drug: PF-07985631, Drug: PlaceboDrug: PF-07985631 Experimental Pfizer compound which will be SC Drug: Placebo Placebo which will be subcutaneous (SC) |
| Cohort 8 Optional Cohort with dose to be determined, Japanese (4 active: 1 placebo) | Experimental | Drug: PF-07985631, Drug: PlaceboDrug: PF-07985631 Experimental Pfizer compound which will be SC Drug: Placebo Placebo which will be SC |
| Cohort 7 Dose G (6 active: 2 placebo) | Experimental | Drug: PF-07985631, Drug: PlaceboDrug: PF-07985631 Experimental Pfizer compound which will be SC Drug: Placebo Placebo which will be SC |
| Cohort 6 Dose F (6 active: 2 placebo) | Experimental | Drug: PF-07985631, Drug: PlaceboDrug: PF-07985631 Experimental Pfizer compound which will be SC Drug: Placebo Placebo which will be SC |
| Cohort 2 Dose B (3 active: 2 placebo) | Experimental | Drug: PF-07985631, Drug: PlaceboDrug: PF-07985631 Experimental Pfizer compound which will be SC Drug: Placebo Placebo which will be SC |
| Cohort 4 Dose D (6 active: 2 placebo) | Experimental | Drug: PF-07985631, Drug: PlaceboDrug: PF-07985631 Experimental Pfizer compound which will be SC Drug: Placebo Placebo which will be SC |
| Cohort 5 Dose E (6 active: 2 placebo) | Experimental | Drug: PF-07985631, Drug: PlaceboDrug: PF-07985631 Experimental Pfizer compound which will be SC Drug: Placebo Placebo which will be SC |
| Cohort 9 Optional Cohort with dose to be determined, Chinese (4 active: 1 placebo) | Experimental | Drug: PF-07985631, Drug: PlaceboDrug: PF-07985631 Experimental Pfizer compound which will be SC Drug: Placebo Placebo which will be SC |
| Cohort 3 Dose C (6 active: 2 placebo) | Experimental | Drug: PF-07985631, Drug: PlaceboDrug: PF-07985631 Experimental Pfizer compound which will be SC Drug: Placebo Placebo which will be SC |
| Cohort 10 Optional Cohort with dose to be determined (6 active: 2 placebo) | Experimental | Drug: PF-07985631, Drug: PlaceboDrug: PF-07985631 Experimental Pfizer compound which will be SC Drug: Placebo Placebo which will be SC |
| Cohort 11 Optional Cohort with dose to be determined (6 active: 2 placebo) | Experimental | Drug: PF-07985631, Drug: PlaceboDrug: PF-07985631 Experimental Pfizer compound which will be SC Drug: Placebo Placebo which will be SC |
Who may qualify
- Ages
- 18 to 55 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (3 listed)
- Between 18 and 45 years of age who are overtly healthy.
- Japanese/Chinese cohorts only: Adult participants 18 to 55 years of age
- Japanese/Chinese cohorts only: Participants must have 4 biological Japanese/Chinese grandparents who were born in Japan/China.
Key exclusion criteria (21 listed)
- Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).
- Participants with a history of allergic or anaphylactic reaction with any investigative biologic agents.
- History of infections requiring treatment within 28 days prior to Day 1 or any active infection at Day 1.
- Active or latent infection with tuberculosis.
- History of recurrent urinary tract infections AND/OR sinopulmonary infections AND/OR gastrointestinal infections requiring antibiotic treatment.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| PF-07985631Experimental Pfizer compound which will be SC | Drug | Cohort 1 Dose A (3 active: 2 placebo), Cohort 10 Optional Cohort with dose to be determined (6 active: 2 placebo), Cohort 11 Optional Cohort with dose to be determined (6 active: 2 placebo), Cohort 2 Dose B (3 active: 2 placebo), Cohort 3 Dose C (6 active: 2 placebo), Cohort 4 Dose D (6 active: 2 placebo), Cohort 5 Dose E (6 active: 2 placebo), Cohort 6 Dose F (6 active: 2 placebo), Cohort 7 Dose G (6 active: 2 placebo), Cohort 8 Optional Cohort with dose to be determined, Japanese (4 active: 1 placebo), Cohort 9 Optional Cohort with dose to be determined, Chinese (4 active: 1 placebo) |
| PlaceboPlacebo which will be SC | Drug | Cohort 1 Dose A (3 active: 2 placebo), Cohort 10 Optional Cohort with dose to be determined (6 active: 2 placebo), Cohort 11 Optional Cohort with dose to be determined (6 active: 2 placebo), Cohort 2 Dose B (3 active: 2 placebo), Cohort 3 Dose C (6 active: 2 placebo), Cohort 4 Dose D (6 active: 2 placebo), Cohort 5 Dose E (6 active: 2 placebo), Cohort 6 Dose F (6 active: 2 placebo), Cohort 7 Dose G (6 active: 2 placebo), Cohort 8 Optional Cohort with dose to be determined, Japanese (4 active: 1 placebo), Cohort 9 Optional Cohort with dose to be determined, Chinese (4 active: 1 placebo) |
Primary outcome
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAE)
Time frame: Baseline (Day 1) up to 83 days after last dose of study drug (approximately up to 3 months)
Number of Participants With Clinically Significant Abnormal Laboratory Parameters
Time frame: Baseline (Day 1) up to 83 days after last dose of study drug (approximately up to 3 months)
Number of Participants With Vital Signs Values Meeting Categorical Summarization Criteria
Time frame: Baseline (Day 1) up to 83 days after last dose of study drug (approximately up to 3 months)
Number of Participants With Notable Electrocardiogram (ECG) Values
Time frame: Baseline (Day 1) up to 83 days after last dose of study drug (approximately up to 3 months)
5 secondary outcomes
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) as data permit
Time frame: Predose (Day 1) up to 83 days after last dose of study drug (approximately up to 3 months)
Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) as data permit
Time frame: Predose (Day 1) up to 83 days after last dose of study drug (approximately up to 3 months)
Maximum Observed Plasma Concentration (Cmax) as data permit
Time frame: Predose (Day 1) up to 83 days after last dose of study drug (approximately up to 3 months)
Time to Reach Maximum Observed Plasma Concentration (Tmax) as data permit
Time frame: Predose (Day 1) up to 83 days after last dose of study drug (approximately up to 3 months)
Plasma Decay Half-Life (t1/2) as data permit
Time frame: Predose (Day 1) up to 83 days after last dose of study drug (approximately up to 3 months)
Results and safety
The study was stopped early (reason given: The estimated benefit-risk profile of PF-07985631 is not anticipated to be favorable in the expected population to be treated). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Aug 2026.
- To obtain contact information for a study center near you, click here.Link provided by the sponsor.
- Individual participant dataSharing planned: No. Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Related trials for Healthy
Not yet recruitingObservational study
Collection and Distribution of Blood Components From Healthy Donors for In Vitro Research Use
Blood Donors, Apheresis
Not yet recruitingPhase 1
Dynamic Magnetic Resonance Imaging of Human Subarachnoid Space Using Intrathecal Gadolinium Contrast
Healthy Volunteers
Enrolling by invitationObservational study
Connors Protocol for the Management and Use of Stored Human Specimens (Stored Human Specimens)
Healthy Volunteer Samples
RecruitingObservational study
Viral Infections in Healthy and Immunocompromised Hosts
Anogenital Herpes, COVID-19
RecruitingPhase 1
A Study in Healthy People to Compare How 2 Different Formulations of Vicadrostat / Empagliflozin Tablets Are Taken up in the Body
Healthy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Pfizer CT.gov Call Center study director
Pfizer
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing PF-07985631 in people with Healthy, run by Pfizer at 1 site in Australia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 21 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 18 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Australia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study was stopped early (reason given: The estimated benefit-risk profile of PF-07985631 is not anticipated to be favorable in the expected population to be treated). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAE) (time frame: Baseline (Day 1) up to 83 days after last dose of study drug (approximately up to 3 months)). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Aug 2026.